By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: EverBridge Group and Cosmotec Forge Landmark Partnership
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > News > EverBridge Group and Cosmotec Forge Landmark Partnership
EverBridge Group and Cosmotec Forge Landmark Partnership
News

EverBridge Group and Cosmotec Forge Landmark Partnership

Last updated: 15/09/2025 7:37 AM
Published: 15/09/2025
Share
SHARE

SHANGHAI, Sept. 15, 2025 /PRNewswire/ — EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market.

- Advertisement -

This strategic collaboration underscores EverBridge Group’s leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence.

- Advertisement -

Simultaneously, the partnership underscores Cosmotec’s best-in-class digital commercialization platform, which accelerates market access for international medical devices and enables targeted engagement with clinical end-users.

- Advertisement -

“EverBridge Group’s portfolio demonstrates outstanding clinical efficiency and user-friendly design, aligning perfectly with Japanese physicians’ pursuit of advanced therapeutic solutions,” stated Suguru Ominato, CEO of Cosmotec. “By integrating M3’s academic platforms with our localized commercialization expertise, we will accelerate the adoption of these devices across the Japanese market.”

- Advertisement -

“Cosmotec’s digital commercialization model delivers both efficiency and accessibility, which aligns perfectly with our vision for equitable healthcare innovation,” said Jay Wang, CEO of EverBridge Group. “By navigating Japan’s rigorous technical and regulatory landscape, this partnership not only delivers transformative solutions to patients but also enhances our global R&D synergy. Lowering barriers to advanced care through innovation and ecosystem collaboration remains central to our globalization journey.”

- Advertisement -

About EverBridge Group

- Advertisement -

EverBridge Group is a leading medical technology group in Asia, committed to providing global customers with cutting-edge, high-quality, and affordable medical technologies. Our rapidly expanding product portfolio covers three major therapeutic areas: peripheral vascular, neuroscience, and oncology. Supported by Six specialized R&D and lean production centers, we offer top-tier OEM/ODM services in areas including balloons, catheters, stents, surface engineering, and active medical devices.

- Advertisement -

We collaborate extensively with outstanding enterprises worldwide, building a bridge for medical technology innovation between Asia and the rest of the world. Our goal is to offer healthcare professionals and patients globally better treatment options through advanced and accessible solutions.

- Advertisement -

For more information, please visit the official website: www.everbridgemed.com

- Advertisement -

Contact: Ann Chen, communications@everbridgemed.com

- Advertisement -

Photo – https://mma.prnewswire.com/media/2764432/DSC02892.jpg

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/everbridge-group-and-cosmotec-forge-landmark-partnership-302553681.html

- Advertisement -
Celebrating 100 years, Duas Rodas unveils its new brand DR Flavors & Ingredients and begins a new cycle of evolution
Pioneering Sustainable Solutions: The Art of Living’s 4R Approach
Final Call for Entries: Submission Deadline Nears for the Seoul Design Award 2025
Mayilaa — A Newton Cinema Production — Announces World Premiere at the 55th International Film Festival Rotterdam (IFFR)
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
TAGGED:andcosmoteceverbridgeforgegrouplandmarknewspartnership
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Seek Common Ground, Connect the World, the 6th Qingdao Multinationals Summit Opens Today
News

Seek Common Ground, Connect the World, the 6th Qingdao Multinationals Summit Opens Today

20/06/2025
Grand Cinemaz Expands Footprint with the Launch of its 2 Multiplexes in a Single Day – Ghaziabad & Saharanpur – A Vision to Redefine Cinema Across India
EL CHATO TAKES THE NO.1 SPOT IN LATIN AMERICA’S 50 BEST RESTAURANTS 2025
CCTV+: Drums, Dragons, and Dynasty: 26th Qianlong Lantern Festival Ignites Living Heritage
Total number of shares and voting rights in Zealand Pharma as of December 31, 2025
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?